Introduction
PRES is a serious neurological disorder of (sub) acute onset characterized by abnormalities in cerebral white matter. Clinical symptoms may include headaches, visual disturbances, disorders of consciousness, seizures, or focal neurological deficits [1]. PRES develops frequently in the context of cytotoxic medication, (pre) eclampsia, sepsis, renal disease, or autoimmune disorders [1].
Among drugs, PRES may complicate calcineurin inhibitors such as cyclosporine A (CSA). Organ-transplanted patients and those with nephrotic syndrome on this drug have reportedly experienced this complication [2, 3, and 4].
This article reports a unique and challenging case of a 16-year-old boy admitted to our department with steroid-resistant nephrotic syndrome (NS) and COVID-19 in February 2022. SARS-CoV-2 infection misled the diagnosis of CSA-induced PRES.